MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
It tests for the presence or absence of ribonucleic acid (RNA) of Dengue (Type 1, 2 4) in serum or plasma from patients suspected of dengue viral infection.
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
HTL will build, validate and operate a botulinum manufacturing facility in the US
The World Health Organisation (WHO), has felt the need to conduct this training to build local capacities in poor countries to bridge the gap and enhance local production
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
Subscribe To Our Newsletter & Stay Updated
